TG Therapeutics Inc. (TGTX)

14.40
NASDAQ : Health Technology
Prev Close 14.70
Day Low/High 14.35 / 14.80
52 Wk Low/High 7.25 / 17.35
Avg Volume 1.47M
Exchange NASDAQ
Shares Outstanding 75.58M
Market Cap 1.11B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

15 Biotech Firms That Have Strong Potential to Be Acquired: Jefferies

'Balance sheets are flush with cash and there is a need to grow for large health care companies,' Jefferies analysts wrote.

TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2017 Financial Results And Business Update

TG Therapeutics, Inc. Announces Fourth Quarter And Year-End 2017 Financial Results And Business Update

Investor conference call to be held today, Thursday March 8, 2018 at 8:30am ET  

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2017 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Fourth Quarter And Year-End 2017 Financial Results And Business Update

Investor Conference Call to be held Thursday, March 8, 2018 at 8:30am ET  

First Week of April 20th Options Trading For TG Therapeutics (TGTX)

First Week of April 20th Options Trading For TG Therapeutics (TGTX)

Investors in TG Therapeutics Inc saw new options become available this week, for the April 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new April 20th contracts and identified one put and one call contract of particular interest.

TG Therapeutics, Texas Instruments, ConocoPhillips: 'Mad Money' Lightning Round

TG Therapeutics, Texas Instruments, ConocoPhillips: 'Mad Money' Lightning Round

Jim Cramer spotlights TG Therapeutics, Texas Instruments, ConocoPhillips, SemGroup, and Energous.

Just Wait For It: Cramer's 'Mad Money' Recap (Tuesday 2/27/18)

Just Wait For It: Cramer's 'Mad Money' Recap (Tuesday 2/27/18)

Jim Cramer says that sometimes, you just have to sit back and wait for more compelling buying opportunities.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

First Week of TGTX February 16th Options Trading

First Week of TGTX February 16th Options Trading

Investors in TG Therapeutics Inc saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TGTX options chain for the new February 16th contracts and identified one put and one call contract of particular interest.

Why 2018 Will Be Better for Biotech Deals Than 2017

Why 2018 Will Be Better for Biotech Deals Than 2017

Analysts see a year of robust deal action ahead due in part to clarity from a tax standpoint.

TG Therapeutics, Inc. To Present At The 36th Annual J.P. Morgan Healthcare Conference

TG Therapeutics, Inc. To Present At The 36th Annual J.P. Morgan Healthcare Conference

Presentation Scheduled for Thursday, January 11, 2018 at 7:30am PT

Interesting TGTX Put And Call Options For August 2018

Interesting TGTX Put And Call Options For August 2018

Investors in TG Therapeutics Inc saw new options begin trading this week, for the August 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TG Therapeutics Stock Sees Short Interest Move 11.2% Lower

TG Therapeutics Stock Sees Short Interest Move 11.2% Lower

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 2,012,255 share decrease in total short interest for TG Therapeutics Inc , to 15,880,967, a decrease of 11.25% since 11/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

TG Therapeutics, Inc. Recaps Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Recaps Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

Investor and Analyst Reception to be Held on Sunday December 10, 2017 at 8:00pm ET at the Ritz Carlton Atlanta (Downtown) with Presentations by Leading Clinical Investigators

TG Therapeutics Announces Initiation Of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial In Follicular Lymphoma

TG Therapeutics Announces Initiation Of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial In Follicular Lymphoma

TGR-1202 (umbralisib) selected as the PI3K Delta inhibitor to be used in this multiple arm comparison study

TG Therapeutics, Inc. Provides Business Update And Reports Third Quarter 2017 Financial Results

TG Therapeutics, Inc. Provides Business Update And Reports Third Quarter 2017 Financial Results

Investor Conference Call to be Held Today, Wednesday, November 8, 2017 at 8:30am ET

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2017 Financial Results And Business Update

TG Therapeutics, Inc. To Host Conference Call On Third Quarter 2017 Financial Results And Business Update

Investor Conference Call to be held Wednesday, November 8, 2017 at 8:30am ET

TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

TG Therapeutics, Inc. Announces Data Presentations At The Upcoming 59th American Society Of Hematology Annual Meeting

Investor and Analyst Reception to be Held on Sunday December 10, 2017 at 8:00pm ET at the Ritz Carlton Atlanta (Downtown) with Presentations by Leading Clinical Investigators

Commit To Buy TG Therapeutics At $5, Earn 21% Using Options

Commit To Buy TG Therapeutics At $5, Earn 21% Using Options

Investors eyeing a purchase of TG Therapeutics Inc shares, but tentative about paying the going market price of $8.28/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $5 strike, which has a bid at the time of this writing of $1.05.

TheStreet Quant Rating: D- (Sell)